bioRxivCancer BiologyPreprint
The landscape of extrachromosomal circular DNA in medulloblastoma
O. S. Chapman, J. Luebeck, S. Wani, A. Tiwari, M. Pagadala, S. Wang, J. D. Larson, J. T. Lange, I. T.-L. Wong, S. R. Dehkordi, S. Chandran, M. Adam, Y. Lin, E. Juarez, J. T. Robinson, S. Sridhar, D. M. Malicki, N. Coufal, M. Levy, J. R. Crawford, S. L. Pomeroy, J. Rich, R. Scheuermann, H. Carter, J. Dixon, , L. Chavez
Abstract
Extrachromosomal circular DNA (ecDNA) is an important driver of aggressive tumor growth, promoting high oncogene copy number, intratumoral heterogeneity, accelerated evolution of drug resistance, enhancer rewiring, and poor outcome. ecDNA has been reported in medulloblastoma (MB), the most common malignant pediatric brain tumor, but the ecDNA landscape and its association with specific MB subgroups, its impact on enhancer rewiring, and its potential clinical implications, are not known. We assembled a retrospective cohort of 468 MB patient samples with available whole genome sequencing (WGS) data covering the four major MB subgroups WNT, SHH, Group 3 and Group 4. Using computational methods for the detection and reconstruction of ecDNA1, we find ecDNA in 82 patients (18%) and observe that ecDNA+ MB patients are more than twice as likely to relapse and three times as likely to die of disease. In addition, we find that individual medulloblastoma tumors often harbor multiple ecDNAs, each containing different amplified oncogenes along with co-amplified non-coding regulatory enhancers. ecDNA was substantially more prevalent among 31 analyzed patient-derived xenograft (PDX) models and cell lines than in our patient cohort. By mapping the accessible chromatin and 3D conformation landscapes of MB tumors that harbor ecDNA, we observe frequent candidate "enhancer rewiring" events that spatially link oncogenes with co-amplified enhancers. Our study reveals the frequency and diversity of ecDNA in a subset of highly aggressive tumors and suggests enhancer rewiring as a frequent oncogenic mechanism of ecDNAs in MB. Further, these results demonstrate that ecDNA is a frequent and potent driver of poor outcome in MB patients.
- organism: human
- assay: whole-genome sequencing
- research focus: clustering
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Preservation and Clonal Behavior of Extrachromosomal DNA in Patient-Derived Xenograft Models of Childhood Cancers
Rishaan Kenkre, Owen S. Chapman, … Lukas Chávez·Genome MedicinePeer-reviewed·May 28, 2026
- An Atlas of Extrachromosomal DNA Structures Illuminates Its Evolution and Biogenesis in Cancer
Chee‐Hong Wong, Kuo‐Chen Wei, … Chia‐Lin Wei·bioRxiv·Dec 25, 2025
- Frequent extrachromosomal oncogene amplification drives aggressive tumors
H. Kim, N. Nguyen, … R. G. W. Verhaak·bioRxiv·Nov 28, 2019
- Extrachromosomal DNA micronucleation constrains tumour fitness andimproves patient survival
Lotte Brückner, Robin Xu, … Anton George Henssen·bioRxiv·Apr 15, 2025
- A mitotic restriction point for extrachromosomal DNA hubs in cancer cells
Xiaowei Yan, Ivy Tsz Lo Wong, … Howard Y. Chang·bioRxiv·Oct 9, 2026
- Pan-cancer characterization and clinical outcome of ecDNA-enhancer mediated transcriptional dysregulation
Tengwei Zhong, Huan Zhao, … Zhiyun Guo·bioRxiv·Sep 6, 2023